Yes. Metformin 500 mg is generally a low dose for weight loss and often serves as a starting dose. Most research showing modest average weight change used total daily doses closer to 1,500–2,000 mg. Metformin is FDA-approved for type 2 diabetes, not weight loss, so this use needs clinician oversight. 1, 2
Is 500 mg of metformin a low dose for weight loss?
For weight-related goals, 500 mg of metformin is usually considered low. It may be the full starting amount for an extended-release product or one part of an immediate-release starting schedule. It is lower than the daily amounts used in many studies of metformin and weight change. 1, 2
Metformin hydrochloride is a biguanide medicine. It is sold as immediate-release metformin and extended-release metformin (ER or XR), including products known as Glucophage, Glucophage XR, Fortamet, and Glumetza. It is approved to improve blood sugar control in type 2 diabetes; using it for weight loss, insulin resistance, prediabetes, or PCOS-related weight concerns may be off-label. 1, 9
A lower dose is not automatically ineffective, and a higher dose is not automatically better. A clinician weighs the intended benefit against nausea, diarrhea, gas, stomach discomfort, kidney function, other health conditions, and the rare risk of lactic acidosis. 1
What counts as a low, standard, and high dose of metformin?
There is no single dose category that fits every metformin product. Still, 500 mg per day is low compared with the 1,500–2,000 mg daily range often seen in weight-related studies. The exact label maximum depends on whether the product is immediate-release or extended-release. 1, 4
Immediate-release metformin
The FDA label for immediate-release metformin describes an adult starting schedule of 500 mg twice daily or 850 mg once daily with meals. Label-based increases are made gradually based on blood sugar response and tolerability; the maximum labeled daily dose is 2,550 mg. 1
Extended-release metformin (ER/XR)
Extended-release metformin releases the medicine more slowly. Its label describes a 500 mg once-daily starting dose with the evening meal, with gradual increases when needed. Many ER products have a labeled maximum of 2,000 mg per day, though product labels differ. 1
Maximum daily dose
A 2,000–2,550 mg daily maximum appears on common metformin labels, depending on the formulation. That is a product limit, not a target for every person. Higher amounts can increase gastrointestinal side effects and may not be appropriate with reduced kidney function. 1
| Total daily amount | How it is commonly viewed | What it may mean for weight-related use | Key caution |
|---|---|---|---|
| 500 mg | Low or starting dose | Below doses used in many weight-related studies | Digestive side effects can still occur. 1 |
| 1,000 mg | Lower-to-mid daily range | Above a low starting amount, but still below many study doses | Formulation and kidney function matter. 1 |
| 1,500–2,000 mg | Common study range | Several studies of modest weight change used doses in this range | More medicine may also mean less tolerability. 2, 4 |
| Above 2,000 mg | High for many products | Not necessary or appropriate for everyone | Follow the specific product label and clinician assessment. 1 |
Why do many people start metformin at 500 mg?
The main reason is tolerability. Starting at 500 mg can give the digestive system time to adjust before a clinician considers a change. Diarrhea, nausea, abdominal discomfort, gas, and indigestion are among metformin’s most common side effects. 1
In the Diabetes Prevention Program (DPP), gastrointestinal symptoms were more common in the metformin group than in the placebo group. Those effects often improve over time, but persistent symptoms are a valid reason for a clinician to slow, pause, lower, or reconsider a dose change. 2
The FDA label provides dose-adjustment schedules for diabetes treatment, but those schedules are not personal instructions. A clinician considers the formulation, blood sugar goals, symptoms, kidney function, age, and other medicines before changing a dose. 1
What metformin dose is used for weight loss in studies?
Most evidence comes from people with type 2 diabetes, prediabetes, insulin resistance, or PCOS—not from people taking metformin solely for weight loss. The DPP used 1,700 mg daily, which is well above 500 mg per day, and average weight change was modest. 2, 3
Diabetes Prevention Program: 1,700 mg per day
In the DPP, 3,234 adults at high risk for type 2 diabetes were assigned to intensive lifestyle change, placebo, or metformin 850 mg twice daily. Over an average 2.8 years, the metformin group lost about 2.1 kg on average and had a lower incidence of diabetes than the placebo group. Individual results varied, and gastrointestinal symptoms were more common with metformin. 2
What reviews of metformin and body weight find
A 2020 meta-analysis found that metformin was associated with a small reduction in body mass index among people with obesity. Effects varied by population and treatment duration. It also found larger changes in some analyses using doses above 1,500 mg daily, but this does not show that every person needs or can tolerate that amount. 4
For a closer look at evidence by condition, see our guides to metformin for insulin resistance and whether metformin causes weight loss. 4, 9
How much weight can you lose on 500 mg versus a higher dose?
There is no reliable number for weight loss on 500 mg metformin alone. Because 500 mg is commonly a starting amount and has not been studied as a stand-alone weight-loss dose in large trials, it is reasonable to expect any average effect at that dose to be limited. 1, 2
Long-term DPP follow-up found that metformin was linked with modest sustained weight loss for some participants compared with placebo. That does not mean the same result will happen for an individual, and it does not make metformin an FDA-approved obesity medicine. 3
| Dose pattern or study | What the evidence suggests | What it cannot tell you |
|---|---|---|
| 500 mg daily | Usually a low starting amount; direct weight-loss trial evidence at this dose alone is limited. 1 | It cannot predict an individual result. |
| 1,700 mg daily in the DPP | Average weight loss was about 2.1 kg over 2.8 years. 2 | This was a prediabetes trial, not a trial of 500 mg for weight loss. |
| Long-term DPP follow-up | Some participants maintained modest weight differences over time. 3 | Results varied and do not guarantee weight loss. |
How long does metformin take to affect weight?
Metformin’s effect on blood sugar can begin before any noticeable change on the scale. Weight change usually develops over months, not days or a single week, when it occurs. In the DPP, outcomes were measured over an average of 2.8 years. 2
A clinician may assess more than body weight, including blood sugar markers, eating patterns, medication tolerance, and kidney function. For practical expectations over an earlier time frame, read our review of two-month metformin weight-loss results. 1, 3
Who might stay on a lower dose of metformin?
Some people remain at a lower amount because kidney function and side-effect tolerance make a higher dose a poor fit. The goal is not to reach the highest possible dose; it is to use a dose with an acceptable benefit-risk balance for that person. 1
Kidney function and eGFR
Estimated glomerular filtration rate, or eGFR, measures kidney filtration. Metformin is contraindicated when eGFR is below 30 mL/min/1.73 m². The FDA label also says starting metformin is not recommended when eGFR is 30–45 mL/min/1.73 m²; ongoing treatment in that range requires clinical reassessment. 1
Side effects and lactic acidosis risk
Digestive symptoms may limit dosing. Metformin also carries a boxed warning for lactic acidosis, a rare but serious buildup of lactate in the blood. Risk rises with significant renal impairment and can be affected by factors such as hypoxic illness, excessive alcohol intake, liver impairment, and some contrast imaging procedures. 1
How does metformin compare with GLP-1 medications for weight loss?
Metformin and GLP-1 receptor agonists work differently. Metformin mainly reduces liver glucose production and improves insulin sensitivity. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors; these medicines affect appetite, fullness, and glucose regulation. 1, 5, 7
In major trials, semaglutide and tirzepatide produced larger average weight loss than metformin studies. That difference comes with different safety considerations: nausea, vomiting, diarrhea, constipation, and abdominal pain are common, and both drug labels carry warnings including thyroid C-cell tumor warnings and pancreatitis-related precautions. 5, 6, 7, 8
| Option | FDA status for weight loss | Evidence for weight change | Important risks and limits | Access |
|---|---|---|---|---|
| Metformin | Not FDA-approved for weight loss; approved for type 2 diabetes. 1 | Usually modest average weight change in relevant studies. 2, 4 | GI effects, kidney-function limits, and rare lactic acidosis. 1 | Prescription medication; often available as a lower-cost generic. |
| Semaglutide: Wegovy, Ozempic, and compounded semaglutide | Wegovy is approved for chronic weight management in eligible patients; Ozempic is not approved for weight loss. Compounded semaglutide is not FDA-approved. 5, 10 | In STEP 1, semaglutide 2.4 mg weekly with lifestyle intervention produced 14.9% mean weight loss at 68 weeks. 6 | GI effects and thyroid-tumor warnings; not for people with certain thyroid cancer histories. 5 | Brand and compounded prescriptions are different products; compounded outcomes are not established through FDA review. |
| Tirzepatide: Zepbound, Mounjaro, and compounded tirzepatide | Zepbound is approved for chronic weight management in eligible adults; Mounjaro is approved for type 2 diabetes. Compounded tirzepatide is not FDA-approved. 7, 10 | In SURMOUNT-1, tirzepatide produced substantial mean weight reductions over 72 weeks. 8 | GI effects and thyroid-tumor warnings; important contraindications require clinical review. 7 | Brand and compounded prescriptions are different products; compounded outcomes are not established through FDA review. |
If you are comparing these options, our guide to the best diabetes drugs for weight loss explains the evidence and trade-offs in more detail. 5, 7
How can you get GLP-1 care through Chia?
At Chia, a licensed US provider can review your health history, current medicines, relevant labs, and weight-management goals to decide whether a GLP-1 option is clinically appropriate. We offer compounded semaglutide by injection, with plans currently starting at $249 per month, and compounded tirzepatide as tablets or injections, with plans currently starting at $249 per month for tablets and $299 per month for injections. Microdosing plans are available for both treatments when a provider determines they are appropriate. Compounded medications are not FDA-approved. 10
The visit is fully online. After the health questionnaire, a provider reviews eligibility and prescribes only when clinically appropriate; a prescription is never guaranteed. Medications are compounded by US state-licensed 503A pharmacies, shipped to the patient’s door, and dosing is guided and adjusted by the care team through the patient portal. 1, 10
| Chia GLP-1 option | Available form | What may matter in a discussion with a provider |
|---|---|---|
| Compounded semaglutide | Injection | Injection is the available Chia form; plans currently start at $249 per month. |
| Compounded tirzepatide | Tablets or injection | Form preference, clinical history, tolerance, and provider judgment all matter; plans currently start at $249 per month for tablets and $299 per month for injections. |
3-min quiz
Explore GLP-1 options with a licensed provider
A medical evaluation is required, and a prescription is not guaranteed. You can review Chia’s semaglutide options and tirzepatide options before starting the eligibility quiz. Compounded medications are prepared by state-licensed 503A pharmacies and are not FDA-approved.
Frequently asked questions
It can be. A 500 mg amount is commonly part of a starting regimen, especially for extended-release metformin. The appropriate dose depends on the formulation, blood sugar response, kidney function, and side effects. 1
The labeled starting schedule differs by formulation. Immediate-release and extended-release products have different directions, which is why patients should follow the prescription label and their clinician’s plan rather than compare doses across products. 1
Digestive side effects are most common. The most serious labeled risk is rare lactic acidosis, which is why clinicians assess kidney function and other risk factors before and during treatment. 1
3-min quiz
Start with an online clinical evaluation
Our providers can review whether a GLP-1 option may fit your history and goals; a medical evaluation is required and a prescription is not guaranteed. Compounded medications from state-licensed 503A pharmacies are not FDA-approved.
References
- 1.U.S. Food and Drug Administration. Metformin Hydrochloride Tablets and Extended-Release Tablets: Prescribing Information. 2023.
- 2.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
- 3.Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012.
- 4.Pu R, Shi D, Gan T, et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Therapeutic Advances in Endocrinology and Metabolism. 2020.
- 5.U.S. Food and Drug Administration. Wegovy (semaglutide) injection: Prescribing Information. 2025.
- 6.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- 7.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection: Prescribing Information. 2025.
- 8.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- 9.American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- 10.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2025.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.




